NCT07134478View on ClinicalTrials.gov

Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

December 24, 2024

Study Completion Date

June 1, 2026

Conditions
Healthy Subjects
Interventions
DRUG

HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi

"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg will be administered every morning from Day 6 to Day 14. On the morning of Day 15, rifampicin capsules 600 mg and HSK31858 tablets 40 mg will be co-administered."

Trial Locations (1)

Unknown

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT07134478 - Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects | Biotech Hunter | Biotech Hunter